ZA9710186B - Process for substituted pyridines - Google Patents

Process for substituted pyridines

Info

Publication number
ZA9710186B
ZA9710186B ZA9710186A ZA9710186A ZA9710186B ZA 9710186 B ZA9710186 B ZA 9710186B ZA 9710186 A ZA9710186 A ZA 9710186A ZA 9710186 A ZA9710186 A ZA 9710186A ZA 9710186 B ZA9710186 B ZA 9710186B
Authority
ZA
South Africa
Prior art keywords
substituted pyridines
pyridines
substituted
Prior art date
Application number
ZA9710186A
Other languages
English (en)
Inventor
Keith Michael De Vries
Robert Lee Dow
Stephen Wayne Wright
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of ZA9710186B publication Critical patent/ZA9710186B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA9710186A 1996-11-14 1997-11-12 Process for substituted pyridines ZA9710186B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3088096P 1996-11-14 1996-11-14

Publications (1)

Publication Number Publication Date
ZA9710186B true ZA9710186B (en) 1999-05-12

Family

ID=21856496

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9710186A ZA9710186B (en) 1996-11-14 1997-11-12 Process for substituted pyridines

Country Status (32)

Country Link
US (1) US6291489B1 (fr)
EP (1) EP0938476B1 (fr)
JP (1) JP3510635B2 (fr)
KR (1) KR20000053314A (fr)
CN (1) CN1237160A (fr)
AP (1) AP805A (fr)
AR (1) AR010584A1 (fr)
AT (1) ATE319687T1 (fr)
AU (1) AU4634697A (fr)
BG (1) BG103393A (fr)
BR (1) BR9712951A (fr)
CA (1) CA2270386C (fr)
CO (1) CO4930261A1 (fr)
DE (1) DE69735433D1 (fr)
EA (1) EA199900375A1 (fr)
GT (1) GT199700118A (fr)
HR (1) HRP970612A2 (fr)
ID (1) ID18898A (fr)
IL (1) IL129688A0 (fr)
IS (1) IS5029A (fr)
MA (1) MA24401A1 (fr)
MY (1) MY132507A (fr)
NO (1) NO992296L (fr)
OA (1) OA11044A (fr)
PA (1) PA8441401A1 (fr)
PE (1) PE10299A1 (fr)
TN (1) TNSN97172A1 (fr)
TR (1) TR199901063T2 (fr)
UY (1) UY24774A1 (fr)
WO (1) WO1998021184A1 (fr)
YU (1) YU22099A (fr)
ZA (1) ZA9710186B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010042518A (ko) * 1998-04-08 2001-05-25 한스 루돌프 하우스, 헨리테 브룬너, 베아트리체 귄터 신규 제초제
US6090942A (en) * 1998-10-15 2000-07-18 Pfizer Inc. Process and intermediates for a β3 -adrenergic receptor agonist
HUP0200092A3 (en) 1999-02-16 2003-02-28 Kaneka Corp Substituted acetylpyridine derivatives and process for the preparation of intermediates for optically active betha-3 agonist by the use of the same
US6455734B1 (en) * 2000-08-09 2002-09-24 Magnesium Diagnostics, Inc. Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
EP1078924B1 (fr) * 1999-07-23 2004-10-20 Pfizer Products Inc. Intermédiaires et un procédé pour la préparation des agonistes du récepteur beta3-adrénergique [2000/16]
WO2003033468A1 (fr) * 2001-10-17 2003-04-24 Kaneka Corporation Procede de preparation de derives de (s)-$g(a)-halomethylpyridine-methanol
WO2003072573A1 (fr) * 2002-02-27 2003-09-04 Pfizer Products Inc. Formes cristallines de (r)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol
JP2005520501A (ja) 2002-02-27 2005-07-14 ファイザー・プロダクツ・インク β３−アドレナリン作用性レセプターアゴニストを製造するのに有用な方法及び中間体
US6864268B2 (en) 2002-02-27 2005-03-08 Pfizer Inc. β3 adrenergic receptor agonists
EP1424079A1 (fr) * 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Combinaison d'un agoniste du beta-3-récepteur et d'un inhibiteur de recaptage de sérotonine et/ou norépinéphrine
KR100751163B1 (ko) 2003-05-09 2007-08-22 에프. 호프만-라 로슈 아게 알파-1 아드레날린 작용물질로서의 메틸 인돌 및 메틸피롤로피리딘
US7977359B2 (en) 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
GB2431927B (en) 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
US8399666B2 (en) 2005-11-04 2013-03-19 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
JP5791500B2 (ja) 2008-05-23 2015-10-07 パンミラ ファーマシューティカルズ，エルエルシー． ５−リポキシゲナーゼ活性化タンパク質阻害剤
US8546431B2 (en) 2008-10-01 2013-10-01 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4358455A (en) 1980-12-23 1982-11-09 Merck & Co., Inc. Aralkylamindethanol heterocyclic compounds
US5019578A (en) 1987-11-27 1991-05-28 Merck & Co., Inc. β-adrenergic agonists
BR9406823A (pt) 1993-06-14 1996-03-26 Pfizer Aminas secundárias e agentes anti-diabéticos e antiobesidade
IL113410A (en) 1994-04-26 1999-11-30 Merck & Co Inc Substituted sulfonamides having an asymmetric center and pharmaceutical compositions containing them
CA2220399A1 (fr) 1995-05-10 1996-11-14 Pfizer Inc. Agonistes du recepteur .beta.-adrenergique
EP0828712A1 (fr) 1995-05-10 1998-03-18 Pfizer Inc. Agonistes du recepteur beta-adrenergique

Also Published As

Publication number Publication date
US6291489B1 (en) 2001-09-18
PE10299A1 (es) 1999-02-10
CN1237160A (zh) 1999-12-01
CA2270386C (fr) 2004-08-03
WO1998021184A1 (fr) 1998-05-22
MA24401A1 (fr) 1998-07-01
AR010584A1 (es) 2000-06-28
JP2000504347A (ja) 2000-04-11
ATE319687T1 (de) 2006-03-15
YU22099A (sh) 2001-09-28
AU4634697A (en) 1998-06-03
EP0938476B1 (fr) 2006-03-08
ID18898A (id) 1998-05-20
IL129688A0 (en) 2000-02-29
CO4930261A1 (es) 2000-06-27
UY24774A1 (es) 1998-05-05
CA2270386A1 (fr) 1998-05-22
OA11044A (en) 2002-02-20
NO992296D0 (no) 1999-05-12
BG103393A (en) 2000-07-31
BR9712951A (pt) 1999-12-07
KR20000053314A (ko) 2000-08-25
DE69735433D1 (de) 2006-05-04
GT199700118A (es) 1999-05-05
AP9701147A0 (en) 1998-01-31
EP0938476A1 (fr) 1999-09-01
NO992296L (no) 1999-05-12
TR199901063T2 (xx) 1999-08-23
HRP970612A2 (en) 1998-08-31
TNSN97172A1 (fr) 2005-03-15
JP3510635B2 (ja) 2004-03-29
IS5029A (is) 1999-04-16
MY132507A (en) 2007-10-31
AP805A (en) 2000-01-28
PA8441401A1 (es) 2000-05-24
EA199900375A1 (ru) 1999-12-29

Similar Documents

Publication Publication Date Title
HRP970330A2 (en) Cycloalkano pyridines
GB9616573D0 (en) Process
GB9626429D0 (en) Process
GB9609441D0 (en) Process
SG46782A1 (en) Bicyclic-fused pyridines
GB9618952D0 (en) Process
EP0880388A4 (fr) Procede d'etherification-hydrogenation
AP9701147A0 (en) Process for substituted pyridines
IL122454A (en) Process for forming bubble-pack
GB9602046D0 (en) Process
GB9726197D0 (en) Process
GB2319771B (en) Process
GB9626570D0 (en) Process for making benzisothiazolin-3-ones
GB9619076D0 (en) Process
GB9618835D0 (en) Process
GB2316403B (en) Process
GB9617658D0 (en) Process
GB9618926D0 (en) Cable-making process
GB9617968D0 (en) Process for making dihydropyrimidinones
GB9600866D0 (en) Process
GB9613633D0 (en) Process
GB9600766D0 (en) Process
GB9616451D0 (en) Process
GB9616419D0 (en) Process
GB9616418D0 (en) Process